FDA Grants Accelerated Approval to GSK's Neladalkib for ALK-Positive Lung Cancer
GSK is trading near its 52-week low of $45.805 (8.1% above the low) on light trading volume (0.4× avg).
Summary
The FDA granted accelerated approval to neladalkib, marketed in the US as Nelkarmi, the ALK kinase inhibitor GSK picked up through its $10.6B all-cash acquisition of Nuvalent in July. The drug is cleared as a late-line option for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer, and the decision landed ahead of the Nov. 27 target action date. The approval covers patients with one prior alectinib or two or more prior ALK TKIs plus platinum chemotherapy, with confirmed ORR of 49% (33/67; 95% CI: 37%, 62%) and ORR of 32% (50/155; 95% CI: 24%, 40%) respectively in the ALKOVE-1 Phase 1/2 trial, which enrolled 700 patients with ALK-positive solid tumours and included 222 previously treated ALK-positive NSCLC patients in its primary efficacy analysis. Intracranial ORR was 55% (11/20; 95% CI: 32%, 77%), including 25% complete responses, in patients previously treated with alectinib as their only prior ALK TKI, and 26% (14/53; 95% CI: 15%, 40%), including 11% complete responses, in those who received two or more prior ALK TKIs and chemotherapy; duration of response lasted 6 or more months in 76% and 12 or more months in 52% of alectinib-only responders, and 6 or more months in 69% and 12 or more months in 51% of responders with two or more prior ALK TKIs and chemotherapy. The most common (≥20%) adverse reactions were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue, and permanent discontinuation due to adverse reactions occurred in 5% of patients, most frequently from hepatotoxicity. The approval follows the FDA's Breakthrough Therapy and Orphan Drug designations, adds a commercial asset to a specialty portfolio that grew 15% CER in Q3, though full approval still hinges on a confirmatory trial, and is the second US regulatory win in a month for GSK, following Jemperli's October approval in locally advanced rectal cancer.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — Nelkarmi's approval covers patients with one prior alectinib or two or more prior ALK TKIs plus platinum chemotherapy, with ORR of 49% and 32% respectively in ALKOVE-1.
- Response by Prior Treatment — Confirmed ORR was 49% (33/67; 95% CI: 37%, 62%) in patients with alectinib as their only prior ALK TKI and 32% (50/155; 95% CI: 24%, 40%) in those with two or more prior ALK TKIs plus chemotherapy.
- Intracranial Response — Intracranial ORR was 55% (11/20; 95% CI: 32%, 77%) with 25% complete responses in alectinib-only patients and 26% (14/53; 95% CI: 15%, 40%) with 11% complete responses in those with two or more prior ALK TKIs and chemotherapy.
- Duration of Response — DOR lasted 6 or more months in 76% and 12 or more months in 52% of alectinib-only responders; for patients with two or more prior ALK TKIs and chemotherapy, 69% and 51% respectively.
- Safety Profile — Most common (≥20%) adverse reactions were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue; permanent discontinuation due to adverse reactions occurred in 5%, most often hepatotoxicity.
- Trial Population — ALKOVE-1 (NCT05384626) enrolled 700 patients with ALK-positive solid tumours; the primary efficacy analysis included 222 patients with previously treated ALK-positive NSCLC.
- Regulatory Designations — Nelkarmi is the US brand name for neladalkib; the approval follows the FDA's Breakthrough Therapy and Orphan Drug designations.
All 11 details
- Intracranial ORR 55% (11/20; 95% CI: 32%, 77%), including 25% complete responses, in patients previously treated with alectinib as their only prior ALK TKI.
- Intracranial ORR 26% (14/53; 95% CI: 15%, 40%), including 11% complete responses, in patients who received two or more prior ALK TKIs and chemotherapy.
- DOR 6 or more months in 76% of responders and 12 or more months in 52% of responders for alectinib-only patients.
- DOR 6 or more months in 69% of responders and 12 or more months in 51% of responders for patients with two or more prior ALK TKIs and chemotherapy.
- Most common (≥20%) adverse reactions: hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.
- Permanent discontinuation of Nelkarmi due to adverse reactions occurred in 5% of patients; most frequent adverse reaction leading to permanent discontinuation was hepatotoxicity.
- ALKOVE-1 (NCT05384626) enrolled 700 patients with ALK-positive solid tumours; primary efficacy analysis included 222 patients with previously treated ALK-positive NSCLC.
- Approval follows the FDA's Breakthrough Therapy and Orphan Drug designations.
- Confirmed ORR 49% (33/67; 95% CI: 37%, 62%) in patients previously treated with alectinib as their only prior ALK TKI.
- ORR 32% (50/155; 95% CI: 24%, 40%) in patients with two or more prior ALK TKIs and chemotherapy.
- Nelkarmi is the brand name for neladalkib in the US accelerated approval.
At the time of this announcement, GSK was trading at $49.51 on NYSE in the Life Sciences sector, with a market capitalization of approximately $102B. The 52-week trading range was $45.81 to $61.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.